Elevance Health 3Q 2026: Revenue $51.43B, EPS $6.27— 10-Q Summary
Elevance Health reported 3Q 2026 revenue of $51.43B, up 1.4% YoY, and EPS of $6.27, up 17.9% YoY. Growth was driven by premium rate increases and CarelonRx, despite a 1.1% decline in medical membership. The company also launched a transformation program for efficiency and cost management initiatives.
How this was made
The 30-second read
Why it matters
The earnings beat may prompt short‑term buying interest, but longer‑term performance will depend on how the company addresses membership attrition and cost pressures.
Market read
First‑time disclosure of Q3 2026 results provides fresh data for traders; the modest beat could generate a small price move.
What to watch
The transformation program and cost‑management initiatives may take time to materialize, limiting near‑term upside.
Background
Elevance Health (ELV) released its third‑quarter 2026 earnings via a 10‑Q filing, highlighting modest revenue growth and higher EPS despite a dip in medical membership.
Ticker impact
Elevance Health filed its 3Q 2026 10‑Q reporting $51.43B revenue and $6.27 diluted EPS, a modest YoY increase.
slight upward pressure as the market prices in the revenue and EPS beat
The company posted higher revenue and EPS versus the same quarter last year, with premium rate increases and CarelonRx growth offsetting membership declines.
Market effects
The health‑care services sector may see modest support as premium rate hikes demonstrate pricing power.
U.S. health‑care stocks could experience a small lift in the afternoon session.
Limited; the news is primarily relevant to U.S. investors focused on health‑care insurers.
Counterpoint
Membership declines and cost pressures could weigh on margins, suggesting the beat may be temporary.
Key entities
- CompanyElevance Health
U.S. health‑care insurer reporting Q3 2026 results.
